Teva (ADR: TEVA) has been a darling for investors in the
generic drug sector. Even as recently as last year, investors were eager to see
the growth of the company and along with it, the stock price. But then second
quarter earnings were reported and Teva stock price hit the fan as they say.
Teva stock price has since cratered 45% since earnings were
released and there is no sign of the price coming back. So should investors,
particularly value investors take a look at Teva?
In this post, we will look at Teva stock and see whether or
not there is a value play here or if you are better served putting your
investing dollars elsewhere.
No comments:
Post a Comment